Sadly, some of the strongest characters that stand out in the books didn't make it into any of the Harry Potter movies.
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
It's important to remember the ongoing controversial statements by the creator of the Harry Potter franchise. CBR supports ...
The microfinance sector faces mounting challenges as gross NPAs nearly doubled in H1, signaling deep stress in asset quality. India's markets ended the week on a sharp downturn, with the Sensex and ...
Lupin Ltd., incorporated in the year 1983, is a Large Cap company (having a market cap of Rs 1,07,542.63 Crore) operating in Pharmaceuticals sector. Lupin Ltd. key Products/Revenue Segments include ...
Submission of warning letter received from NSE with regard to corporate announcements submitted in letter head of the Company where-in PAN of the Company was mentioned. Intimation of loss of Share ...